HRP20131109T1 - Postupak proizvodnje derivata diamina - Google Patents

Postupak proizvodnje derivata diamina Download PDF

Info

Publication number
HRP20131109T1
HRP20131109T1 HRP20131109AT HRP20131109T HRP20131109T1 HR P20131109 T1 HRP20131109 T1 HR P20131109T1 HR P20131109A T HRP20131109A T HR P20131109AT HR P20131109 T HRP20131109 T HR P20131109T HR P20131109 T1 HRP20131109 T1 HR P20131109T1
Authority
HR
Croatia
Prior art keywords
toluenesulfonic acid
process according
compound represented
formula
acid monohydrate
Prior art date
Application number
HRP20131109AT
Other languages
English (en)
Inventor
Takeo Koyama
Original Assignee
Daiichi Sankyo Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Company, Limited filed Critical Daiichi Sankyo Company, Limited
Publication of HRP20131109T1 publication Critical patent/HRP20131109T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/28Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups

Claims (12)

1. Postupak proizvodnje spoja predstavljenog sljedećom formulom (A), koji obuhvaća korake: (a) miješanje spoja predstavljenog formulom (B): [image] s p-toluensulfonskom kiselinom ili monihidratom p-toluensulfonske kiseline pri manje od 1 molarnog ekvivalenta u odnosu na spoj predstavljen formulom (B) u otapalu uz zagrijavanje; (b) dodavanje dodatne p-toluensulfonske kiseline ili monohidrata p-toluensulfonske kiseline u pomiješanu otopinu uz hlađenje, pri čemu dodatna p-toluensulfonska kiselina ili monohidrat p-toluensulfonske kiseline se dodaje u takvoj količini da je njezin ili njegov ukupni molarni ekvivalent u odnosu na p-toluensulfonsku kiselinu ili monohidrat p-toluensulfonske kiseline iz koraka (a) jednak 1 molarni ekvivalent ili više s obzirom na spoj predstavljen formulom (B) iz koraka (a); i (c) zatim omogućavanje da pomiješana otopina kristalizira tako da se dobije spoj predstavljen formulom (A) : [image]
2. Postupak prema zahtjevu 1, pri čemu p-toluensulfonska kiselina ili monohidrat p-toluensulfonske kiseline iz koraka (a) je 0.5 molarni ekvivalent ili više te manje od 1.0 molarni ekvivalent u odnosu na spoj predstavljen formulom (B).
3. Postupak prema zahtjevu 1 ili 2, pri čemu the p-toluensulfonska kiselina ili monohidrat p-toluensulfonske kiseline iz koraka (a) je 0.8 molarni ekvivalent ili više te manje od 1.0 molarni ekvivalent u odnosu na spoj predstavljen formulom (B).
4. Postupak prema bilo kojem od zahtjeva 1 do 3, pri čemu je ukupni molarni ekvivalent p-toluensulfonske kiseline ili monohidrata p-toluensulfonske kiseline iz koraka (a) i dodatne p-toluensulfonske kiseline ili monohidrata p-toluensulfonske kiseline dodanog u koraku (b) između 1.0 molarnog ekvivalenta i 3.0 molarnog ekvivalenta, obuhvaćeno, u odnosu na spoj predstavljen formulom (B) iz koraka (a).
5. Postupak prema bilo kojem od zahtjeva 1 do 3, pri čemu je ukupni molarni ekvivalent p-toluensulfonske kiseline ili monohidrata p-toluensulfonske kiseline iz koraka (a) i dodatne p-toluensulfonske kiseline ili monohidrata p-toluensulfonske kiseline dodanog u koraku (b) između 1.0 molarnog ekvivalenta i 1.2 molarnog ekvivalenta, obuhvaćeno, u odnosu na spoj predstavljen formulom (B) iz koraka (a).
6. Postupak prema bilo kojem od zahtjeva 1 do 5, pri čemu je otapalo alkohol ili vodeni alkohol.
7. Postupak prema bilo kojem od zahtjeva 1 do 6, pri čemu je otapalo vodeni etanol.
8. Postupak prema bilo kojem od zahtjeva 1 do 7, pri čemu vodeni etanol ima sadržaj vode veći od 0% i manji ili jednak 50%.
9. Postupak prema bilo kojem od zahtjeva 1 do 8, pri čemu se koristi monohidrat p-toluensulfonske kiseline.
10. Postupak prema bilo kojem od zahtjeva 1 do 9, pri čemu je količina otapala od 5 puta do 30 puta (v/w) veća od količine spoja B.
11. Postupak prema bilo kojem od zahtjeva 1 do 10, pri čemu je temperatura zagrijavanja iz koraka (a) 60°C do 80°C.
12. Postupak prema bilo kojem od zahtjeva 1 do 11, pri čemu je temperatura hlađenja iz koraka (b) -20°C do 40°C.
HRP20131109AT 2008-12-17 2013-11-20 Postupak proizvodnje derivata diamina HRP20131109T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008320693 2008-12-17
PCT/JP2009/070874 WO2010071121A1 (ja) 2008-12-17 2009-12-15 ジアミン誘導体の製造方法

Publications (1)

Publication Number Publication Date
HRP20131109T1 true HRP20131109T1 (hr) 2014-01-31

Family

ID=42268792

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20131109AT HRP20131109T1 (hr) 2008-12-17 2013-11-20 Postupak proizvodnje derivata diamina

Country Status (18)

Country Link
US (1) US8404847B2 (hr)
EP (1) EP2371830B1 (hr)
JP (1) JP5305421B2 (hr)
KR (1) KR101463653B1 (hr)
CN (1) CN102256984B (hr)
BR (1) BRPI0923109A8 (hr)
CA (1) CA2747427C (hr)
EG (1) EG26766A (hr)
ES (1) ES2437346T3 (hr)
HK (1) HK1162467A1 (hr)
HR (1) HRP20131109T1 (hr)
IL (1) IL213614A (hr)
MY (1) MY150973A (hr)
RU (1) RU2464271C1 (hr)
SI (1) SI2371830T1 (hr)
TW (1) TWI439464B (hr)
WO (1) WO2010071121A1 (hr)
ZA (1) ZA201104236B (hr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101424843B1 (ko) 2007-03-29 2014-08-13 다이이찌 산쿄 가부시키가이샤 의약 조성물
WO2010104078A1 (ja) * 2009-03-10 2010-09-16 第一三共株式会社 ジアミン誘導体の製造方法
CN102348680B (zh) 2009-03-13 2014-11-05 第一三共株式会社 用于制备光学活性二胺衍生物的方法
JP5692873B2 (ja) * 2010-03-19 2015-04-01 第一三共株式会社 ジアミン誘導体の結晶およびその製造方法
JPWO2015129603A1 (ja) * 2014-02-25 2017-03-30 第一三共株式会社 活性化血液凝固第X因子(FXa)阻害剤の高純度結晶
CN105777779B (zh) * 2014-12-16 2019-03-26 四川海思科制药有限公司 一种对甲苯磺酸依度沙班化合物
EP3318568A1 (en) 2016-11-04 2018-05-09 Esteve Química, S.A. Preparation process of edoxaban tosylate monohydrate
KR102480897B1 (ko) 2019-09-09 2022-12-23 주식회사 종근당 디아민 유도체의 제조방법
KR20220014858A (ko) 2020-07-29 2022-02-07 주식회사 종근당 디아민 유도체의 결정형 및 이의 제조 방법
CN114349770B (zh) * 2020-10-13 2023-02-03 江苏威凯尔医药科技有限公司 一种凝血FXa抑制剂的制备方法
KR102577696B1 (ko) 2020-11-16 2023-09-14 주식회사 보령 에독사반 토실산염 또는 그 수화물의 제조방법

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149855A (en) 1989-12-26 1992-09-22 Mitsubishi Rayon Co., Ltd. Process for racemizing optically active carboxylic acid esters
US5055600A (en) 1990-04-24 1991-10-08 Rockwell International Corporation Glycidyl azide polymer (gap) synthesis by molten salt method
US5677469A (en) 1995-05-18 1997-10-14 Sepracor, Inc. Process for resolving chiral acids with 1-aminoindan-2-ols
JPH11180899A (ja) 1997-12-15 1999-07-06 Mitsui Chem Inc 活性メチレンアルキル化化合物の製造法
JP3680203B2 (ja) 1999-06-01 2005-08-10 東洋化成工業株式会社 4−アセチルアミノベンゼンスルホニルアジドの製造方法
JP2001151724A (ja) 1999-11-19 2001-06-05 Kuraray Co Ltd 光学活性な2,2,4−トリメチル−3−シクロヘキセンカルボン酸の製造方法
TWI290136B (en) 2000-04-05 2007-11-21 Daiichi Seiyaku Co Ethylenediamine derivatives
US7365205B2 (en) 2001-06-20 2008-04-29 Daiichi Sankyo Company, Limited Diamine derivatives
US20050245565A1 (en) * 2001-06-20 2005-11-03 Daiichi Pharmaceutical Co., Ltd. Diamine derivatives
AU2002328596B2 (en) * 2001-08-09 2007-09-20 Daiichi Pharmaceutical Co., Ltd. Diamine derivatives
WO2004058715A1 (ja) 2002-12-25 2004-07-15 Daiichi Pharmaceutical Co., Ltd. ジアミン誘導体
KR20050121712A (ko) 2003-04-08 2005-12-27 노파르티스 아게 유기 화합물
EP2266992A3 (en) 2003-11-12 2011-05-18 Daiichi Sankyo Company, Limited Process for producing thiazole derivative
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
WO2007032498A1 (ja) * 2005-09-16 2007-03-22 Daiichi Sankyo Company, Limited 光学活性なジアミン誘導体およびその製造方法
JP4227629B2 (ja) 2006-04-28 2009-02-18 達實 小野 過熱蒸気を応用した塗装用乾燥焼付装置
WO2008043996A2 (en) 2006-10-09 2008-04-17 Cipla Limited Process for preparing trityl olmesartan medoxomil and olmesartan medoxomil
KR101424843B1 (ko) 2007-03-29 2014-08-13 다이이찌 산쿄 가부시키가이샤 의약 조성물
TW200909437A (en) 2007-06-21 2009-03-01 Daiichi Sankyo Co Ltd Process for the preparation of diamine-derivatives

Also Published As

Publication number Publication date
RU2464271C1 (ru) 2012-10-20
TWI439464B (zh) 2014-06-01
WO2010071121A1 (ja) 2010-06-24
IL213614A (en) 2015-10-29
ZA201104236B (en) 2012-02-29
SI2371830T1 (sl) 2014-01-31
KR101463653B1 (ko) 2014-11-19
JPWO2010071121A1 (ja) 2012-05-31
CN102256984B (zh) 2014-09-03
CN102256984A (zh) 2011-11-23
JP5305421B2 (ja) 2013-10-02
CA2747427A1 (en) 2010-06-24
HK1162467A1 (en) 2012-08-31
US8404847B2 (en) 2013-03-26
CA2747427C (en) 2015-10-13
BRPI0923109A8 (pt) 2016-06-07
ES2437346T3 (es) 2014-01-10
KR20110110100A (ko) 2011-10-06
MY150973A (en) 2014-03-31
EP2371830A4 (en) 2012-07-11
TW201028428A (en) 2010-08-01
EP2371830B1 (en) 2013-10-02
EP2371830A1 (en) 2011-10-05
US20110275821A1 (en) 2011-11-10
BRPI0923109A2 (pt) 2016-02-02
IL213614A0 (en) 2011-07-31
EG26766A (en) 2014-08-18

Similar Documents

Publication Publication Date Title
HRP20131109T1 (hr) Postupak proizvodnje derivata diamina
HRP20180210T1 (hr) Postupak priprave 2-[4-(3- ili 2- fluorbenziloksi)benzilamino]propanamida visokog stupnja čistoće
CN101572187B (zh) 一种中、高压铝电解电容器的电解液的溶质的制备方法
CN103483998B (zh) 钢丝防锈剂及其制备方法
NZ597210A (en) Rebaudioside a composition and method for purifying rebaudioside a
HRP20150885T1 (hr) Postupak za pripremu 4-{4-[({[4-kloro-3-(trifluorometil)-fenil]amino}karbonil)amino]-3-fluorofenoksi}-n-metilpiridin-2-karboksamida, njegovih soli i monohidrata
CN103589413B (zh) 一种油井酸化缓蚀剂及其制备和应用
CN101450295A (zh) 一种高效两性双子表面活性剂及其合成方法
CN105440232A (zh) 一种水溶性甲醚化三聚氰胺甲醛树脂的制备工艺
CN106866937A (zh) 一种新型改性咪唑类环氧树脂潜伏性固化剂及其制备方法
CN106496038A (zh) 一种高选择性的3‑甲基‑2‑硝基苯甲酸的制备方法
CN104193635A (zh) 普瑞巴林的合成方法
Smith et al. Structure, medium, and temperature dependence of acid-catalyzed amide hydrolysis
HRP20120501T1 (hr) Postupak proizvodnje 4'-[[4-metil-6-(1-metil-1h-benzimidazol-2-il)-2-propil-1h-benzimidazol-1-il]metil]bifenil-2-karboksilne kiseline (telmisartan)
CN104449615A (zh) 一种采油用有机酸铬类交联剂及其制备方法
CN103553947B (zh) 一种含羟乙基的双酯基季铵盐的制备方法
HRP20220108T1 (hr) Postupak za proizvodnju vortioksetina hbr alfa-oblika
WO2009063804A1 (ja) N-カルバモイル-tert-ロイシンの製造法
CN101307014A (zh) N-(1-腈基-1,2-二甲基丙基)-2-(2,4-二氯苯氧基)丙酰胺的合成方法
CN107118085B (zh) 一种3,4-庚二酮的合成方法
CN106124715A (zh) 一种碱性酒石酸铜溶液及配制方法
CN105622610A (zh) 一种黄嘌呤化合物的制备方法
CN103421451A (zh) 低成本新型乳胶配方
CN101724375A (zh) 胶水
CN107090067A (zh) 一种全水溶性甲醚化氨基树脂的合成方法